JN403

JN403 is a **selective and orally active small molecule agonist of the nicotinic acetylcholine receptor alpha7 (α7 nAChR)**. It acts as a potent and selective partial agonist at this receptor. JN403 penetrates the blood-brain barrier effectively in rodents via intravenous and oral administration. In preclinical models, JN403 has demonstrated effects on cognition enhancement (improvement in learning and memory), restoration of sensory gating, anxiolytic-like properties, anticonvulsant effects, and reduction of pain. It modulates central nervous system activity and also has anti-inflammatory effects, including downregulation of nitric oxide and cytokine release in microglial culture models. JN403 has been explored in animal studies relating to central nervous system disorders, including Alzheimer’s disease, schizophrenia, epilepsy, and models of inflammatory and neuropathic pain.[1][5][9][8]